The combined global market for MS disease-modifying therapies is set to grow at annual rate of 8.1 per cent from 2010 to 2015, according to a new market research report by BCC Research.
The study, titled “Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets,” forecasts that along with this, sales are predicted to reach up to $16.7bn by the end of 2015; a steep rise from $11.3bn this year.
Within this, sales of small molecule MS disease-modifying drugs are expected to see huge growth rates from 2010 to 2015, as the segment is currently estimated to be worth $3.6bn and is likely to double up to $7.9bn at a compound annual growth rate of 17.4 per cent by 2015.
The authors say “biologics represent the largest class of MS disease-modifying therapies by sales and by number of approved therapies.”
To that end they predict that biologics, a sector valued at $7.8bn in 2010, will reach a value of $8.8bn in 2015, increasing at a compound annual growth rate (CAGR) of 2.5 per cent.